Teriparatide vs Tirzepatide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Teriparatide vs Tirzepatide: they're closely matched on evidence (7 vs 7.8/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Too Close to Call

Teriparatide and Tirzepatide are closely matched across evidence, studies, and safety.

Teriparatide1 win

Tirzepatide1 win

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Ter7.0

Teriparatide

Too few graded studiesLimited safety

Tir7.8

Tirzepatide

Too few graded studiesLimited safety

Evidence

Evidence Score

7/10

Studies: 307

Meta-analyses: 47

Level: Strong

Evidence Score

Best7.8/10

Studies: 133

Meta-analyses: 42

Level: Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Bone healthToo few graded studies202
Fracture & skeletal outcomesToo few graded studies44
Safety profileToo few graded studies7

Verdict

Too few graded studies

Top outcomes

Weight managementToo few graded studies80
Glycemic & metabolic controlToo few graded studies53
Heart & blood pressureToo few graded studies20

Dosage & timing

Recommended Dosage:

20 micrograms once daily by subcutaneous injection (the approved osteoporosis dose; PRESCRIPTION ONLY)

Warnings

PRESCRIPTION DRUG, NOT A SUPPLEMENT — an FDA-approved osteoporosis medication reserved for patients at high fracture risk; should only be used under a prescription and medical supervision.
HISTORICAL BOXED WARNING for osteosarcoma: teriparatide originally carried an FDA boxed warning and a 2-year lifetime-use limit because high lifetime doses caused osteosarcoma in RATS. A 15-year US postmarketing surveillance study (2003-2016) did not find an increased osteosarcoma incidence in treated adults, which does not establish zero risk. The EU Forsteo label limits total treatment to 24 months and says that course should not be repeated during a patient’s lifetime. In November 2020, the FDA removed FORTEO’s osteosarcoma boxed warning. The US label now says treatment beyond two years in a lifetime should be considered only if the patient remains at, or returns to, high fracture risk.
In the EU, Forsteo is contraindicated with metabolic bone disease other than primary or glucocorticoid-induced osteoporosis (including Paget’s disease and hyperparathyroidism), unexplained raised alkaline phosphatase, previous radiation therapy to the skeleton, and skeletal malignancy or bone metastases. The US FORTEO label instead places osteosarcoma-risk groups under an avoid-use warning: open epiphyses, metabolic bone disease such as Paget’s disease, bone metastases or skeletal malignancy, skeletal radiation and hereditary predisposition.
Can cause transient hypercalcemia and orthostatic (postural) hypotension — inject where you can sit or lie down for the first doses.
Requires a daily subcutaneous injection (a refrigerated pen) — a meaningful adherence burden.
Not for fracture HEALING — the evidence is for fracture PREVENTION and bone-density gain; the healing-acceleration literature is mixed.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous injection (prefilled pen)

Recommended Dosage:

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.
Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.
A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.
FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.
Not for cosmetic or off-label use without a medical indication and supervision.
May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.
Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

Safety

Limited safetyTie

Drug Interactions:

Digoxin (moderate)
Calcium / vitamin D supplements (mild)

Side Effects:

Hypercalcemia (transient)Orthostatic hypotension / dizzinessLeg cramps

Contraindications:

Osteosarcoma-risk conditions: in the EU (Forsteo) a contraindication with metabolic bone disease other than primary or glucocorticoid-induced osteoporosis (including Paget’s disease), unexplained raised alkaline phosphatase, previous radiation therapy to the skeleton, and skeletal malignancy or bone metastases. The US FORTEO label instead says to avoid use with open epiphyses, metabolic bone disease such as Paget’s disease, bone metastases or skeletal malignancy, skeletal radiation and hereditary predisposition
Pre-existing hypercalcemia or hyperparathyroidism

Limited safetyTie

Drug Interactions:

Oral contraceptives (moderate)
Insulin and sulfonylureas (moderate)
Oral medications generally (moderate)

Side Effects:

NauseaDiarrheaVomiting

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple endocrine neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

What you'll notice

🦴 Reduced vertebral fracturespositive

Over ~18-24 months of daily use

🛡️ Reduced nonvertebral fragility fracturespositive

Over ~18-24 months

📊 Bone-density gainspositive

Detectable by ~3 months

🧪 Transient hypercalcemiatrade-off

Hours after each dose

🩸 Strong glycemic controlpositive

Weeks to months

⚖️ Large weight losspositive

Months (dose-escalated over ~20 weeks)

😴 Reduced sleep-apnea severitypositive

Weeks to months

🤢 GI side effects (common)negative

Mostly during titration

Key studies

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

N Engl J Med (2001) · Rct · n=1637

Pivotal Fracture Prevention Trial: 1637 postmenopausal women with prior vertebral fractures randomized to PTH(1-34) 20 or 40 microg/day or placebo, median 21 months

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.

Lancet (2018) · Rct · n=1360

Head-to-head double-blind, double-dummy RCT of teriparatide 20 microg/day vs risedronate 35 mg/week in 1360 women with severe osteoporosis over 24 months

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

N Engl J Med (2007) · Rct · n=428

18-month randomized, double-blind, controlled head-to-head trial in 428 patients with glucocorticoid-induced osteoporosis

All Teriparatide studies

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

N Engl J Med (2021) · Rct · n=1879

Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg

Tirzepatide Once Weekly for the Treatment of Obesity.

N Engl J Med (2022) · Rct · n=2539

72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

N Engl J Med (2025) · Rct · n=751

Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide

All Tirzepatide studies

Frequently asked questions

Is Teriparatide better than Tirzepatide?

Both Teriparatide and Tirzepatide are closely matched — the best choice depends on your specific health goals.

Can I take Teriparatide and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Semaglutide vs Teriparatide Liraglutide vs Teriparatide Teriparatide vs Thiamine Semaglutide vs Tirzepatide Liraglutide vs Tirzepatide Thiamine vs Tirzepatide

Still deciding between Teriparatide and Tirzepatide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Teriparatide details Tirzepatide details

Warnings

PRESCRIPTION DRUG, NOT A SUPPLEMENT — an FDA-approved osteoporosis medication reserved for patients at high fracture risk; should only be used under a prescription and medical supervision.

HISTORICAL BOXED WARNING for osteosarcoma: teriparatide originally carried an FDA boxed warning and a 2-year lifetime-use limit because high lifetime doses caused osteosarcoma in RATS. A 15-year US postmarketing surveillance study (2003-2016) did not find an increased osteosarcoma incidence in treated adults, which does not establish zero risk. The EU Forsteo label limits total treatment to 24 months and says that course should not be repeated during a patient’s lifetime. In November 2020, the FDA removed FORTEO’s osteosarcoma boxed warning. The US label now says treatment beyond two years in a lifetime should be considered only if the patient remains at, or returns to, high fracture risk.

In the EU, Forsteo is contraindicated with metabolic bone disease other than primary or glucocorticoid-induced osteoporosis (including Paget’s disease and hyperparathyroidism), unexplained raised alkaline phosphatase, previous radiation therapy to the skeleton, and skeletal malignancy or bone metastases. The US FORTEO label instead places osteosarcoma-risk groups under an avoid-use warning: open epiphyses, metabolic bone disease such as Paget’s disease, bone metastases or skeletal malignancy, skeletal radiation and hereditary predisposition.

Can cause transient hypercalcemia and orthostatic (postural) hypotension — inject where you can sit or lie down for the first doses.

Requires a daily subcutaneous injection (a refrigerated pen) — a meaningful adherence burden.

Not for fracture HEALING — the evidence is for fracture PREVENTION and bone-density gain; the healing-acceleration literature is mixed.

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.

Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.

A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.

FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.

Not for cosmetic or off-label use without a medical indication and supervision.

May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.

Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Frequently asked questions

Is Teriparatide better than Tirzepatide?

Both Teriparatide and Tirzepatide are closely matched — the best choice depends on your specific health goals.

Can I take Teriparatide and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.